X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-06-01 | ATNF | 180 Life Sciences Corp. | Steinman Lawrence | Dir | P - Purchase | $1.23 | +18,000 | 48,129 | +60% | +$22,068 | ||||||
2023-05-31 | CALC | Calcimedica, Inc. | Leheny A. Rachel | CEO, 10% | P - Purchase | $4.21 | +1,000 | 744,326 | 0% | +$4,210 | ||||||
| M | 2023-05-30 | CALC | Calcimedica, Inc. | Bjerkholt Eric | Dir | P - Purchase | $4.14 | +255 | 3,684 | +7% | +$1,055 | |||||
2023-05-30 | CALC | Calcimedica, Inc. | Roberts Eric W | Chief Business Officer, 10% | P - Purchase | $3.86 | +2,000 | 768,287 | 0% | +$7,723 | ||||||
| DM | 2023-05-30 | XENE | Xenon Pharmaceuticals Inc. | Pimstone Simon N. | Dir | S - Sale+OE | $38.90 | -131,245 | 6,000 | -96% | -$5,104,970 | |||||
| M | 2023-05-30 | RAIN | Rain Oncology Inc. | Tang Kevin C | 10% | P - Purchase | $1.06 | +1,088,273 | 3,740,341 | +41% | +$1,158,764 | |||||
| D | 2023-05-31 | VTYX | Ventyx Biosciences, Inc. | Sandborn William J. | See Remarks | S - Sale+OE | $34.26 | -10,629 | 83,051 | -11% | -$364,155 | |||||
| M | 2023-05-30 | HCWB | Hcw Biologics Inc. | Wong Hing C | CEO | P - Purchase | $1.55 | +5,000 | 15,311,468 | 0% | +$7,750 | |||||
2023-05-30 | IRWD | Ironwood Pharmaceuticals Inc | McCourt Thomas A | CEO | S - Sale | $10.70 | -26,632 | 758,284 | -3% | -$284,962 | ||||||
| M | 2023-05-30 | HCWB | Hcw Biologics Inc. | Winer Gary M | Dir | P - Purchase | $1.51 | +1,350 | 14,350 | +10% | +$2,043 | |||||
| D | 2023-05-31 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $37.67 | -12,500 | 445,224 | -3% | -$470,875 | |||||
2023-05-25 | VACC | Vaccitech Plc | Wright Robin | Dir | P - Purchase | $2.66 | +13,750 | 48,256 | +40% | +$36,612 | ||||||
| D | 2023-06-01 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $209.11 | -6,000 | 36,599 | -14% | -$1,254,677 | |||||
| D | 2023-06-01 | MRUS | Merus N.V. | Shuman Harry | VP Controller, PAO | S - Sale+OE | $21.48 | -575 | 5,442 | -10% | -$12,351 | |||||
2023-05-30 | VRTX | Vertex Pharmaceuticals Inc / Ma | Arbuckle Stuart A | EVP, COO | S - Sale | $329.82 | -82 | 56,696 | 0% | -$27,045 | ||||||
| M | 2023-05-30 | COLL | Collegium Pharmaceutical, Inc | Ciaffoni Joseph | Pres, CEO | S - Sale | $21.88 | -62,543 | 337,544 | -16% | -$1,368,704 | |||||
2023-05-30 | VRTX | Vertex Pharmaceuticals Inc / Ma | Ambrose Kristen | SVP, Chief Accounting Officer | S - Sale | $329.82 | -289 | 6,838 | -4% | -$95,318 | ||||||
| M | 2023-05-18 | NATR | Natures Sunshine Products Inc | Brower Nathan G | EVP, GC | S - Sale | $10.97 | -11,396 | 49,053 | -19% | -$124,969 | |||||
2023-05-31 | ATNF | 180 Life Sciences Corp. | McGovern Jr. Donald A. | Dir | P - Purchase | $1.15 | +10,000 | 30,099 | +50% | +$11,470 | ||||||
2023-05-31 | NVCT | Nuvectis Pharma, Inc. | Bentsur Ron | COB, CEO, 10% | P - Purchase | $17.28 | +330 | 3,229,179 | 0% | +$5,702 | ||||||
| D | 2023-05-31 | PRTA | Prothena Corp Public Ltd Co | Malecek Michael J | GC | S - Sale+OE | $64.64 | -5,000 | 0 | -100% | -$323,223 | |||||
2023-05-31 | ZNTL | Zentalis Pharmaceuticals, Inc. | Gallagher Cam | Pres | S - Sale | $26.27 | -27,768 | 463,502 | -6% | -$729,506 | ||||||
2023-05-26 | ZNTL | Zentalis Pharmaceuticals, Inc. | Bunker Kevin D. | Chief Scientific Officer | S - Sale | $30.02 | -80,000 | 880,507 | -8% | -$2,401,248 | ||||||
| D | 2023-05-30 | KDNY | Chinook Therapeutics, Inc. | Greenman William Mariner | Dir | S - Sale+OE | $23.30 | -1,155 | 23,643 | -5% | -$26,912 | |||||
2023-05-31 | EYEN | Eyenovia, Inc. | Gandolfo John P | CFO | P - Purchase | $2.79 | +2,000 | 8,000 | +33% | +$5,580 | ||||||
| M | 2023-05-25 | HCWB | Hcw Biologics Inc. | Byam Rebecca | CFO | P - Purchase | $1.64 | +40,000 | 460,188 | +10% | +$65,544 | |||||
2023-05-30 | ASMB | Assembly Biosciences, Inc. | Delaney William E IV | Chief Scientific Officer | S - Sale | $0.96 | -4,232 | 112,205 | -4% | -$4,046 | ||||||
2023-05-30 | ZVRA | Zevra Therapeutics, Inc. | Watton Corey Michael | Dir | P - Purchase | $5.11 | +400 | 400 | New | +$2,042 | ||||||
2023-05-26 | EYEN | Eyenovia, Inc. | Kern Bren | COO | P - Purchase | $2.73 | +2,500 | 2,500 | New | +$6,825 | ||||||
2023-05-26 | OTLC | Oncotelic Therapeutics, Inc. | Trieu Vuong | COB, CEO, 10% | P - Purchase | $0.03 | +126,888 | 114,697,130 | 0% | +$4,327 | ||||||
2023-05-30 | SONN | Sonnet Biotherapeutics Holdings, Inc. | Dyrness Albert D. | Dir | P - Purchase | $0.47 | +23,255 | 28,962 | +407% | +$10,883 | ||||||
2023-05-30 | DOMH | Dominari Holdings Inc. | Wool Kyle Michael | Dir | P - Purchase | $2.59 | +2,000 | 288,839 | +1% | +$5,180 | ||||||
2023-05-25 | ANNX | Annexon, Inc. | Bain Capital Life Sciences Investors, LLC | 10% | P - Purchase | $2.13 | +300,000 | 5,701,926 | +6% | +$639,720 | ||||||
| D | 2023-05-30 | ALKS | Alkermes Plc. | Nichols Christian Todd | SVP, Chief Commercial Officer | S - Sale+OE | $28.93 | -27,134 | 40,984 | -40% | -$784,862 | |||||
2023-05-26 | SPPI | Spectrum Pharmaceuticals Inc | Brennan Nora | CFO | S - Sale | $1.10 | -32,387 | 567,828 | -5% | -$35,496 | ||||||
| M | 2023-05-25 | INVA | Innoviva, Inc. | Denner Alexander J | 10% | P - Purchase | $13.04 | +200,000 | 7,200,000 | +3% | +$2,608,707 | |||||
| M | 2023-05-25 | AVTX | Avalo Therapeutics, Inc. | Caissa Capital Management Ltd. | 10% | P - Purchase | $2.79 | +2,671 | 1,567,671 | 0% | +$7,464 | |||||
2023-05-25 | PIRS | Pieris Pharmaceuticals, Inc. | Kiritsy Christopher P | Dir | P - Purchase | $0.85 | +10,000 | 20,000 | +100% | +$8,500 | ||||||
2023-05-26 | EYEN | Eyenovia, Inc. | Mather Charles E IV | Dir | P - Purchase | $2.49 | +3,000 | 77,544 | +4% | +$7,470 | ||||||
2023-05-24 | ETST | Earth Science Tech, Inc. | Saumat Giorgio R. | CEO, 10% | P - Purchase | $0.01 | +5,000,000 | 105,465,476 | +5% | +$25,000 | ||||||
2023-05-24 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | 10% | P - Purchase | $0.59 | +18,000 | 38,885,985 | 0% | +$10,705 | ||||||
| DM | 2023-05-25 | MNKD | Mannkind Corp | Castagna Michael | CEO | S - Sale+OE | $4.55 | -150,000 | 2,526,735 | -6% | -$681,803 | |||||
| D | 2023-05-25 | VIRX | Viracta Therapeutics, Inc. | Chevallard Daniel R. | CFO, COO | S - Sale+OE | $1.42 | -3,635 | 92,277 | -4% | -$5,160 | |||||
| D | 2023-05-24 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO | S - Sale+OE | $41.41 | -31,655 | 45,602 | -41% | -$1,310,931 | |||||
2023-05-18 | DOMH | Dominari Holdings Inc. | Wool Kyle Michael | Dir | P - Purchase | $2.54 | +58 | 286,839 | 0% | +$148 | ||||||
2023-05-24 | CNTA | Centessa Pharmaceuticals Plc | Bush Tia L | Chief Quality Officer | S - Sale | $4.48 | -8,000 | 157,102 | -5% | -$35,865 | ||||||
| M | 2023-05-24 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | CEO | P - Purchase | $5.15 | +1,900 | 2,715,145 | 0% | +$9,790 | |||||
| M | 2023-05-25 | LFVN | Lifevantage Corp | Beindorff Michael A | Dir | P - Purchase | $4.32 | +5,000 | 110,569 | +5% | +$21,620 | |||||
2023-05-25 | INSM | Insmed Inc | Wise John Drayton | Chief Commercial Officer | S - Sale | $18.95 | -3,366 | 102,681 | -3% | -$63,786 | ||||||
| D | 2023-05-24 | PBH | Prestige Consumer Healthcare Inc. | Sacco Christine | CFO | S - Sale+OE | $60.07 | -55,294 | 26,969 | -67% | -$3,321,511 | |||||
2023-05-26 | ZOM | Zomedica Corp. | Heaton Larry C II | CEO | P - Purchase | $0.19 | +100,000 | 100,000 | New | +$19,090 | ||||||
2023-05-26 | ABCL | Abcellera Biologics Inc. | Booth Andrew | CFO | P - Purchase | $6.85 | +14,500 | 283,959 | +5% | +$99,325 | ||||||
2023-05-26 | ABCL | Abcellera Biologics Inc. | Thermopylae Holdings Ltd. | 10% | P - Purchase | $6.52 | +153,000 | 56,012,493 | 0% | +$997,728 | ||||||
2023-05-24 | AMPE | Ampio Pharmaceuticals, Inc. | Martino Michael A | CEO | P - Purchase | $0.29 | +76,890 | 76,890 | New | +$22,121 | ||||||
2023-05-25 | EYEN | Eyenovia, Inc. | Grant Stuart M. | 10% | P - Purchase | $2.65 | +88,247 | 5,194,998 | +2% | +$233,855 | ||||||
| M | 2023-05-24 | SVRA | Savara Inc | Ramsay David A | Dir | P - Purchase | $2.59 | +100,000 | 2,201,142 | +5% | +$258,529 | |||||
2023-05-24 | NVCT | Nuvectis Pharma, Inc. | Bentsur Ron | COB, CEO, 10% | P - Purchase | $17.49 | +200 | 3,228,849 | 0% | +$3,498 | ||||||
| D | 2023-05-23 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, COO | S - Sale+OE | $9.85 | -415 | 660,097 | 0% | -$4,088 | |||||
| D | 2023-05-25 | AKBA | Akebia Therapeutics, Inc. | Hadas Nicole R. | SVP, GC | S - Sale+OE | $1.22 | -63,186 | 524,344 | -11% | -$77,270 | |||||
| D | 2023-05-25 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale+OE | $1.22 | -95,478 | 574,037 | -14% | -$116,760 | |||||
| D | 2023-05-23 | MORF | Morphic Holding, Inc. | Farrell Robert E Jr | SVP Finance, CAO | S - Sale+OE | $60.00 | -10,000 | 23,708 | -30% | -$600,000 | |||||
| M | 2023-05-23 | MORF | Morphic Holding, Inc. | Devaul William | GC, Secretary | S - Sale | $60.03 | -3,902 | 21,094 | -16% | -$234,236 | |||||
2023-05-23 | IGMS | Igm Biosciences, Inc. | Takimoto Chris H | Chief Medical Officer | S - Sale | $12.31 | -1,259 | 54,742 | -2% | -$15,497 | ||||||
2023-05-23 | IGMS | Igm Biosciences, Inc. | Tahir Misbah | CFO | S - Sale | $12.31 | -1,259 | 50,711 | -2% | -$15,497 | ||||||
2023-05-23 | IGMS | Igm Biosciences, Inc. | Schwarzer Fred | CEO, Pres | S - Sale | $12.31 | -1,259 | 318,479 | 0% | -$15,497 | ||||||
2023-05-23 | IGMS | Igm Biosciences, Inc. | Keyt Bruce | Chief Scientific Officer | S - Sale | $12.31 | -982 | 139,071 | -1% | -$12,088 | ||||||
2023-05-23 | IGMS | Igm Biosciences, Inc. | Gauthier George | Chief Commercial Officer | S - Sale | $12.31 | -1,259 | 40,953 | -3% | -$15,497 | ||||||
2023-05-23 | IGMS | Igm Biosciences, Inc. | Decker Lisa Lynn | Chief Business Officer | S - Sale | $12.31 | -1,259 | 41,181 | -3% | -$15,497 | ||||||
2023-05-25 | ZOM | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.19 | +100,000 | 1,600,000 | +7% | +$19,340 | ||||||
| D | 2023-05-23 | KRTX | Karuna Therapeutics, Inc. | Ignelzi Troy A. | CFO | S - Sale+OE | $223.41 | -9,000 | 30,487 | -23% | -$2,010,662 | |||||
2023-05-23 | EYEN | Eyenovia, Inc. | Strahlman Ellen R | Dir | P - Purchase | $3.10 | +10,000 | 53,052 | +23% | +$30,976 | ||||||
2023-05-23 | XOMA | Xoma Corp | Sitko Bradley | Chief Investment Officer | P - Purchase | $19.00 | +850 | 5,850 | +17% | +$16,150 | ||||||
| M | 2023-05-23 | XOMA | Xoma Corp | Hughes Owen | Interim CEO | P - Purchase | $23.63 | +2,000 | 2,000 | New | +$47,258 | |||||
| D | 2023-05-23 | ZTS | Zoetis Inc. | Peck Kristin C | CEO | S - Sale+OE | $176.56 | -13,000 | 57,636 | -18% | -$2,295,335 | |||||
2023-05-24 | PRLD | Prelude Therapeutics Inc | Lim Bryant David | GC, Corp Sec. | P - Purchase | $5.39 | +2,400 | 2,400 | New | +$12,936 | ||||||
2023-05-23 | PRLD | Prelude Therapeutics Inc | Chardonnet Laurent | CFO | P - Purchase | $5.50 | +5,000 | 42,165 | +13% | +$27,500 | ||||||
2023-05-23 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | CEO | P - Purchase | $5.63 | +11,856 | 2,713,245 | 0% | +$66,749 | ||||||
2023-05-25 | LPCN | Lipocine Inc. | Patel Mahesh V. | CEO, Pres | P - Purchase | $5.03 | +8,706 | 107,418 | +9% | +$43,791 | ||||||
2023-05-23 | ARDX | Ardelyx, Inc. | Felsch Robert Ora | See Remarks | S - Sale | $3.65 | -1,046 | 116,158 | -1% | -$3,821 | ||||||
2023-05-23 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $3.65 | -11,357 | 913,019 | -1% | -$41,489 | ||||||
2023-05-23 | ARDX | Ardelyx, Inc. | Grammer Elizabeth A | See Remarks | S - Sale | $3.65 | -2,384 | 330,451 | -1% | -$8,709 | ||||||
2023-05-23 | ARDX | Ardelyx, Inc. | Blanks Robert | See Remarks | S - Sale | $3.65 | -2,835 | 266,134 | -1% | -$10,357 | ||||||
2023-05-23 | ARDX | Ardelyx, Inc. | Renz Justin A | CFO | S - Sale | $3.65 | -2,873 | 336,733 | -1% | -$10,496 | ||||||
2023-05-23 | ARDX | Ardelyx, Inc. | Rodriguez Susan | Chief Commercial Officer | S - Sale | $3.65 | -4,711 | 353,420 | -1% | -$17,210 | ||||||
2023-05-23 | ARDX | Ardelyx, Inc. | Rosenbaum David P. | Chief Development Officer | S - Sale | $3.65 | -3,769 | 562,519 | -1% | -$13,769 | ||||||
2023-05-23 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Medical Officer | S - Sale | $3.65 | -2,583 | 319,430 | -1% | -$9,436 | ||||||
2023-05-23 | PRGO | Perrigo Co Plc | Andersen Svend | EVP, Pres CHCI | P - Purchase | $33.41 | +2,900 | 82,424 | +4% | +$96,902 | ||||||
2023-05-24 | DOMH | Dominari Holdings Inc. | Hayes Anthony | CEO | P - Purchase | $2.75 | +2,000 | 212,681 | +1% | +$5,500 | ||||||
2023-05-24 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $4.68 | -95,576 | 735,263 | -12% | -$447,754 | ||||||
2023-05-24 | MNKD | Mannkind Corp | Castagna Michael | CEO | S - Sale | $4.69 | -150,000 | 2,331,735 | -6% | -$702,780 | ||||||
2023-05-24 | MNKD | Mannkind Corp | Binder Steven B. | CFO | S - Sale | $4.68 | -47,810 | 838,324 | -5% | -$223,512 | ||||||
2023-05-24 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale | $41.70 | -1,527 | 40,355 | -4% | -$63,676 | ||||||
2023-05-22 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale | $40.14 | -4,931 | 140,374 | -3% | -$197,907 | ||||||
2023-05-23 | CALC | Calcimedica, Inc. | Bjerkholt Eric | Dir | P - Purchase | $3.27 | +500 | 3,429 | +17% | +$1,634 | ||||||
2023-05-23 | CALC | Calcimedica, Inc. | Leheny A. Rachel | CEO, 10% | P - Purchase | $3.34 | +3,000 | 743,326 | 0% | +$10,032 | ||||||
| M | 2023-05-22 | CALC | Calcimedica, Inc. | Roberts Eric W | Chief Business Officer, 10% | P - Purchase | $3.03 | +8,000 | 766,287 | +1% | +$24,226 | |||||
2023-05-22 | RAIN | Rain Oncology Inc. | Boxer Capital, LLC | See remarks. | S - Sale | $1.25 | -995,000 | 1,152,212 | -46% | -$1,243,750 | ||||||
2023-05-24 | MRTX | Mirati Therapeutics, Inc. | Christensen Jamie | EVP, Chief Scientific Officer | S - Sale | $45.29 | -619 | 124,123 | 0% | -$28,035 | ||||||
2023-05-24 | RPRX | Royalty Pharma Plc | Legorreta Pablo G. | CEO, COB, 10% | P - Purchase | $32.25 | +150,000 | 3,538,980 | +4% | +$4,837,440 | ||||||
| D | 2023-05-22 | IDYA | Ideaya Biosciences, Inc. | Throne Jason | GC | S - Sale+OE | $23.00 | -500 | 0 | -100% | -$11,500 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |